Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health.
The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
-5 vs industry average
Dexcom’s score of 23 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Dexcom?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has typical carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Dexcom's reported carbon emissions
In 2023, Dexcom, Inc. reported total carbon emissions of approximately 479.6 million kg CO2e. This figure encompasses emissions across all scopes, including Scope 1 emissions of about 6.7 million kg CO2e, Scope 2 emissions of approximately 25.3 million kg CO2e, and Scope 3 emissions amounting to around 479.6 million kg CO2e.
Dexcom's emissions data reflects a commitment to transparency, with disclosures covering all three scopes. Notably, the company has made a near-term commitment to reduce emissions, although specific reduction targets have not been detailed. Previous commitments have been marked as expired, indicating a need for renewed focus on climate action.
The company operates within the healthcare equipment and supplies sector and is headquartered in the United States. While Dexcom has not set a net-zero target, it continues to engage in sustainability initiatives and has reported its emissions data directly from its own operations without cascading from a parent company.
Overall, Dexcom's emissions profile highlights the significant impact of Scope 3 emissions, which represent the majority of its carbon footprint, underscoring the importance of addressing supply chain and product use emissions in future climate strategies.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Dexcom’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Dexcom yet.
Scope 3 top emissions categories
12 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Dexcom
Frequently asked questions
Common questions about Dexcom’s sustainability data and climate commitments
Data year: 2023
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project